Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VRDN
vs
S&P 500
VRDN
S&P 500
Over the past 12 months, VRDN has underperformed S&P 500, delivering a return of -12% compared to S&P 500's +16% growth.
Stocks Performance
VRDN vs S&P 500
Performance Gap
VRDN vs S&P 500
Performance By Year
VRDN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Viridian Therapeutics Inc
Glance View
Viridian Therapeutics is a biotechnology company that develops antibody medicines for serious autoimmune and rare diseases. Its main scientific focus is thyroid eye disease, a condition where the immune system attacks tissue around the eyes and can cause pain, swelling, and vision problems. The company is built around drug discovery and clinical development rather than drug manufacturing or retail sales. Viridian makes money the way most drug developers do: by advancing its own drug candidates through testing and, if they succeed, selling approved medicines to doctors and hospitals. It may also use partnerships or licensing deals to support development. Because it is still a development-stage company, the core value of the business is in its pipeline and the potential for future product sales. What makes Viridian’s business different is that it is focused on a narrow set of diseases where patients often have limited treatment options. That means it is not trying to be a broad pharmaceutical company. Instead, it is trying to build a small number of highly targeted therapies that can become specialist treatments in a few clearly defined markets.
